Neuphoria Therapeutics Inc/$NEUP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
- Ticker
- $NEUP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 8
- Headquarters
- Burlington, United States
- Website
- www.neuphoriatx.com
NEUP Metrics
BasicAdvanced
$21M
-
-$4.95
-
-
Price and volume
Market cap
$21M
52-week high
$21.40
52-week low
$3.19
Average daily volume
316K
Financial strength
Current ratio
14.312
Quick ratio
13.907
Total debt to equity
0.116
Profitability
EBITDA (TTM)
-13.999
Gross margin (TTM)
100.00%
Net profit margin (TTM)
131,387.14%
Operating margin (TTM)
110,239.10%
Effective tax rate (TTM)
2.08%
Management effectiveness
Return on assets (TTM)
-27.97%
Return on equity (TTM)
-62.90%
Valuation
Price to revenue (TTM)
-1,016.185
Price to book
0.7
Price to tangible book (TTM)
1.27
Price to free cash flow (TTM)
-0.786
Free cash flow yield (TTM)
-127.25%
Free cash flow per share (TTM)
-4.874
Growth
Revenue change (TTM)
-100.08%
Earnings per share change (TTM)
-214.58%
3-year revenue growth (CAGR)
-81.27%
10-year revenue growth (CAGR)
-49.69%
3-year earnings per share growth (CAGR)
608.91%
10-year earnings per share growth (CAGR)
67.10%
NEUP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.